GCP
CDAK

GSA Capital Partners’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

GSA Capital Partners’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-101,279
Closed -$635K – 1939
2022
Q1 		$635K Buy
+101,279
New +$636K 0.09% 390

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GSA Capital Partners's CDAK Position: Q2 2022 in Review

GSA Capital Partners sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2022, closing a stake of 101,279 shares — an estimated $635K sold.

GSA Capital Partners first reported a position in CDAK in Q1 2022 and held it in 1 quarter. The position peaked at $635K in Q1 2022. 49 funds tracked by Wall St. Rank hold CDAK as of Q2 2022.

  • GSA Capital Partners reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • GSA Capital Partners sold 101,279 Codiak BioSciences, Inc. Common Stock shares in Q2 2022, an estimated $635K.
  • GSA Capital Partners first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • GSA Capital Partners's Codiak BioSciences, Inc. Common Stock position peaked at $635K in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2022.

Based on GSA Capital Partners's 13F filing for Q2 2022, filed 9 Aug 2022.